Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|September 9, 2020
Targeting Cell Cycle in Breast Cancer: CDK4/6 InhibitorsMichela Piezzo, Stefania Cocco, Roberta Caputo, et al.
Oncology Reports|December 19, 2001
Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotypeAnnamaria Galietta, Claudia Pizzi, Guido Pettinato, et al.
Frontiers in Medicine|August 29, 2022
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern ItalyMarcella Nunziato, Federica Di Maggio, Matilde Pensabene, et al.
BMC Cancer|February 8, 2018
It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literatureMatilde Pensabene, Brigida Stanzione, Ivana Cerillo, et al.
Oncology Reports|February 13, 2003
External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of lifeGiuseppe Di Lorenzo, Riccardo Autorino, Fortunato Ciardiello, et al.
Future Oncology (London, England)|August 22, 2023
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinionRoberta Caputo, Giuseppe Buono, Vincenzo Di Lauro, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Prospective clinical trials of biotherapies in solid tumors: a 5-year surveyAlessandro Ottaiano, Ernesto Mollo, Giuseppe Di Lorenzo, et al.
International Journal of Molecular Sciences|September 9, 2020
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-AnalysisMichela Piezzo, Paolo Chiodini, Maria Riemma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2015
Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening StudyFranca Podo, Filippo Santoro, Giovanni Di Leo, et al.
Plos One|September 3, 2024
Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancerAliana Guerrieri-Gonzaga, Davide Serrano, Patrizia Gnagnarella, et al.
Pageof 3